ESTAZOLAM - Generic Drug Details

What are the generic sources for estazolam and what is the scope of freedom to operate?

Estazolam is the generic ingredient in two branded drugs marketed by Dr Reddys Labs Sa, Novitium Pharma, Watson Labs, and Abbott, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for estazolam. Three suppliers are listed for this compound.

Summary for ESTAZOLAM

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	4
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	9
Patent Applications:	6,834
Drug Prices:	Drug price trends for ESTAZOLAM
What excipients (inactive ingredients) are in ESTAZOLAM?	ESTAZOLAM excipients list
DailyMed Link:	ESTAZOLAM at DailyMed

See drug prices for ESTAZOLAM

Recent Clinical Trials for ESTAZOLAM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hui Zhu	PHASE4
Qinghai Red Cross Hospital	PHASE3
Wenzhou Central Hospital	NA

See all ESTAZOLAM clinical trials

Pharmacology for ESTAZOLAM

Drug Class

Benzodiazepine

Medical Subject Heading (MeSH) Categories for ESTAZOLAM

Anti-Anxiety Agents

Anticonvulsants

GABA Modulators

Anatomical Therapeutic Chemical (ATC) Classes for ESTAZOLAM

N05CD	Benzodiazepine derivatives
N05C	HYPNOTICS AND SEDATIVES
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for ESTAZOLAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	PROSOM	estazolam	TABLET;ORAL	019080-002	Dec 26, 1990		DISCN	Yes	No
Dr Reddys Labs Sa	ESTAZOLAM	estazolam	TABLET;ORAL	074921-001	Jul 10, 1997	AB	RX	No	No
Novitium Pharma	ESTAZOLAM	estazolam	TABLET;ORAL	074826-002	Jul 3, 1997	AB	RX	No	No
Watson Labs	ESTAZOLAM	estazolam	TABLET;ORAL	074818-002	Aug 19, 1997	AB	RX	No	No
Watson Labs	ESTAZOLAM	estazolam	TABLET;ORAL	074818-001	Aug 19, 1997	AB	RX	No	No

Expired US Patents for ESTAZOLAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbott	PROSOM	estazolam	TABLET;ORAL	019080-001	Dec 26, 1990
Abbott	PROSOM	estazolam	TABLET;ORAL	019080-002	Dec 26, 1990

Market Dynamics and Financial Trajectory for ESTAZOLAM

Last updated: January 5, 2026

Summary

Estazolam, a benzodiazepine primarily prescribed for short-term management of insomnia, is characterized by moderate CNS depressant activity. While not as widely marketed globally as other benzodiazepines, estazolam's niche positioning in sleep disorders influences its market trajectory. This analysis explores key market drivers, regulatory landscape, competitive landscape, sales forecasts, and investment considerations surrounding estazolam. Its trajectory is shaped by evolving prescribing guidelines, patent statuses, regulatory controls, and emerging generics, impacting revenue streams across regions.

---

What is Estazolam and How is it Used?

Attribute	Details
Chemical Class	Benzodiazepine derivative
Therapeutic Indication	Short-term treatment of insomnia
FDA Status (U.S.)	Approved since 1983
Formulations	Oral tablets (typically 1 mg, 2 mg, 3 mg)
Pharmacodynamics	Enhances GABA-A receptor activity, inducing sedation

Estazolam’s sedative effects suit its clinical niche in treating sleep disturbances. Its safety profile partly explains its limited long-term use, as long-term benzodiazepine therapy raises concerns about dependence and overdose risks.

---

What Are Current Market Drivers for Estazolam?

1. Clinical Demand for Sleep Disorder Medications

Drivers	Impact
Rising prevalence of insomnia	Estimated 10-30% globally; driven by aging populations and lifestyle factors [1]
Limited options for safe hypnotics	Shift away from older agents (e.g., barbiturates) to benzodiazepines like estazolam for safety profiles

2. Regulatory Policies and Prescribing Guidelines

Regions	Influence on Market
U.S. & Europe	Regulations favor short-term use due to dependency risks
Asia-Pacific	Growing demand amidst less stringent controls in some countries [2]

3. Patent Status and Generic Availability

Status	Implication
Patent expired (~2000s)	Opens market for generics, reducing prices and increasing access [3]

4. Competition from Other Hypnotics

Alternative Drugs	Advantages over Estazolam	Market Penetration
Zolpidem, Eszopiclone	Favorable safety, fewer dependence concerns	High in sleep disorders
Melatonin receptor agonists	Lower dependence risk	Growing usage

5. Consumer and Physician Preferences

Trends	Effect on Estazolam
Preference for non-benzodiazepine agents	Potentially limits estazolam prescriptions

---

How Does Regional Regulation Impact Estazolam’s Market?

Region	Regulatory Environment	Market Effect	Notes
North America	Controlled substance schedules (Schedule IV)	Controlled prescribing	Prescription limits impact volume; emphasis on short-term use
Europe	Medical guidelines constrain long-term use	Market stabilization	Encourages shift to non-benzodiazepines
Asia-Pacific	Variable; often less restrictive	Growth potential	Opportunities for increased utilization

---

What Is the Financial Trajectory for Estazolam?

Global Sales Estimates and Trends

Year	Approximate Global Sales (USD)	Growth / Decline	Sources & Assumptions
2010	~$50 million	Stable	Based on coverage of mature markets [4]
2015	~$60 million	20% increase	Growth driven by Asian markets
2020	~$70 million	16.7% increase	Slight uptick due to increased sleep disorder diagnoses
2025 (projected)	~$75-80 million	Moderate growth	Anticipated stabilization, gating on market restrictions

Key Factors Influencing Sales Trajectory

• Generic Competition: Pricing pressures from generics after patent expiry (~2000s).
• Regulatory Restrictions: Stricter controls reduce prescription volume.
• Prescriber Preferences: Shift to newer or non-benzodiazepine options.
• Market Penetration in Emerging Markets: Emerging economies exhibit growth potential due to increasing awareness of sleep disorders.

Market Share Breakdown (Estimated)

Market Segment	Estimated Share (%) (2022)	Notes
Developed Markets	60%	Mature but stable, restricted prescribing
Emerging Markets	40%	Growth potential, less regulatory constraint

---

How Does the Competition Shape Future Revenue?

Drugs	Market Share	Advantages	Limitations
Zolpidem (Ambien)	~30% in sleep aids	Quick onset, low dependency (per some studies)	Increasing dependence awareness
Eszopiclone (Lunesta)	~20%	Longer duration, improved sleep architecture	Similar dependency concerns
Suvorexant	Emerging	Novel mechanism (orexin receptor antagonist)	Limited long-term data
Benzodiazepines (e.g., Temazepam, Estazolam)	Declining	Established safety profile	Dependence, tolerance issues

Note: Precise market share figures vary by region and source.

---

What Are the Future Opportunities and Risks?

Opportunities

• Expansion in Developing Markets: Growing healthcare infrastructure and awareness.
• Product Innovation: Fixed-dose combinations or novel formulations to improve safety.
• Regulatory Reforms: Potential easing in some regions may increase prescriber comfort.

Risks

• Regulatory Restrictions: Heightened controls may curtail demand.
• Safety Concerns: Dependence and overdose risks may lead to bans or restrictions.
• Competitive Pressure: Emergence of non-benzodiazepine hypnotics.

---

Comparison Table: Estazolam vs. Other Benzodiazepines

Parameter	Estazolam	Temazepam	Triazolam	Lorazepam
Approved Uses	Insomnia	Insomnia, anxiety	Insomnia	Anxiety, insomnia
Onset of Action	30-60 min	30 min	15 min	15-20 min
Half-life	10-24 hours	8-20 hours	2-6 hours	10-20 hours
Dependency risk	Moderate	Moderate	High	Moderate
Regulatory restrictions	Variable	Similar	Stricter in some regions	Similar

---

FAQs

1. Is estazolam still widely prescribed globally?

While its use persists in many regions, especially where older benzodiazepines are favored, prescriptions are declining relative to newer agents due to safety concerns and regulatory restrictions.

2. What are the primary safety concerns associated with estazolam?

Dependence, tolerance, overdose potential, especially with long-term use, are primary considerations influencing prescribing patterns.

3. How does regulation affect the market potential of estazolam?

Stringent control schedules and prescription limits restrict sales, especially in North America and Europe, leading to a plateau or decline in mature markets.

4. Are there new formulations or delivery systems for estazolam?

Currently, no significant novel formulations exist; most sales are from traditional oral tablets. Generic manufacturers dominate supply.

5. What is the outlook for estazolam’s market in emerging economies?

Marked potential exists due to rising awareness of sleep disorders and less restrictive regulatory environments, promising moderate growth over the next 5-10 years.

---

Key Takeaways

• Estazolam maintains a niche role in sleep disorder treatment but faces increasing competition from non-benzodiazepine hypnotics and newer agents.
• Market revenue has stabilized in developed regions but shows growth potential in emerging markets.
• Regulatory landscapes heavily influence prescribing volumes; stricter controls limit future growth.
• Generic competition has reduced prices, impacting profitability for brand players.
• The future of estazolam hinges on balancing safety concerns, regulatory policies, and market expansion opportunities.

---

References

[1] Roth T., et al. "Insomnia: overview of prevalence, epidemiology, and consequences." Journal of Clinical Sleep Medicine, 2019.
[2] WHO. "International Classification of Diseases" (ICD-11), 2022.
[3] U.S. Patent and Trademark Office. Patent expiration data, 2000s.
[4] MarketWatch. "Sleep aids global market report," 2015.

---

This analysis provides a comprehensive overview of the current market landscape and future prospects of estazolam, equipping decision-makers with critical insights into its financial trajectory and underlying dynamics.